Ontario Institute for Regenerative Medicine (OIRM)   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Toronto Canada (2014)

Organization Overview

First Clinical Trial
2018
NCT03369275
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ontario Institute for Regenerative Medicine | Ontario Institute for Regenerative Medicine (OIRM) | Ontario Institute of Regenerative Medicine (OIRM)

Active Ingredients

Drugs in Phase 2 Trials (2)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

metformin (glucophage) (1 trial)

Drugs in Phase 1 Trials (1)

umbilical cord mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bronchopulmonary Dysplasia (Phase 1)

Hyperplasia (Phase 1)

Inflammation (Phase 2)

Multiple Sclerosis (Phase 2)

Pathologic Processes (Phase 2)

Sclerosis (Phase 2)

Shock (Phase 2)

Shock, Septic (Phase 2)

Systemic Inflammatory Response Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3